Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT07180264
Trastuzumab Deruxtecan in Advanced Breast Cancer
118 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Advanced Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04042701
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
115 Enrollment(s)
30 Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer


Non-small Cell Lung Carcinoma
RECRUITING
NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
88 Enrollment(s)
9 Study location(s)
INTERVENTIONAL (PHASE2)
Early-stage Breast Cancer


Hormone Receptor Positive Breast Carcinoma


Invasive Breast Cancer


Stage II Breast Cancer


Stage IIA Breast Cancer


Stage IIB Breast Cancer


Stage III Breast Cancer
RECRUITING
NCT07025148
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Arterial Disease (CAD)


Percutaneous Coronary Intervention (PCI)
WITHDRAWN
NCT04684212
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF
0 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
Atrial Fibrillation


Left Atrial Appendage Thrombosis


CVA
COMPLETED
NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
663 Enrollment(s)
110 Study location(s)
INTERVENTIONAL (PHASE2)
Hypertension
RECRUITING
NCT05274048
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
18 Enrollment(s)
3 Study location(s)
INTERVENTIONAL (PHASE1)
Gastric Cancer


Gastrointestinal Cancer


HER2 Gene Mutation
ACTIVE_NOT_RECRUITING
NCT03334617
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
528 Enrollment(s)
45 Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer